The planned new directive   is set to implement simpler, more uniform rules on clinical trials in the EU, including making specific provision for low-intervention trials, clarifying the role of ethics committees in the authorisation process, and detailing how to obtain informed consent from patients. There are also firmer rules on transparency, including on negative outcomes of clinical trials.